Disappointing RethinQ Data Is Neither Plus Nor Minus For ICDs – Analysts
This article was originally published in The Gray Sheet
Executive Summary
The St. Jude-sponsored RethinQ trial will not expand the market for cardiac resynchronization therapy defibrillators as the company had hoped, but will not do further damage to the sluggish ICD market, analysts project
You may also be interested in...
7-French Factor: Absence Of Fidelis Lead Gives St. Jude’s Riata A Boost
Medtronic's recall of its Sprint Fidelis ICD leads will have only a small impact on overall implantable defibrillator demand, but the market leader's share will suffer as doctors seek the thinnest leads available, electrophysiologists suggested on an Oct. 29 conference call
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.